Education
About Us
Working with TipRanks
Follow Us
Edesa Biotech Inc (EDSA)
NASDAQ:EDSA
EDSA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.55 - $4.49
Previous CloseN/A
Volume1.31K
Average Volume (3M)73.60K
Market Cap
$19.35M
Enterprise Value$11.12M
Total Cash (Recent Filing)$12.36M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Dec 12, 2025EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding7,037,648
10 Day Avg. Volume196,619
30 Day Avg. Volume73,604
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)7.18
Price to Sales (P/S)0.00
P/FCF Ratio-2.91
Enterprise Value/Market Cap0.57
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-119.02
Enterprise Value/Ebitda-1.91
Forecast
1Y Price Target
$5.00Price Target Upside81.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
Analyst RatingAnalyst assumes coverage of Edesa with a Buy rating and a 12-month price target of $5.
Drug DevelopmentThe lead drug candidate, EB06, has shown favorable safety and tolerability profiles in prior Phase 1 trials.
Regulatory ApprovalHealth Canada has approved Edesa Biotech to conduct a Phase 2 trial of EB06 in moderate to severe nonsegmental vitiligo patients.
Bears Say
Edesa Biotech News
EDSA FAQ
What was Edesa Biotech Inc’s price range in the past 12 months?
Edesa Biotech Inc lowest stock price was $1.55 and its highest was $4.49 in the past 12 months.
What is Edesa Biotech Inc’s market cap?
Edesa Biotech Inc’s market cap is $19.35M.
When is Edesa Biotech Inc’s upcoming earnings report date?
Edesa Biotech Inc’s upcoming earnings report date is Dec 12, 2025 which is in 70 days.
How were Edesa Biotech Inc’s earnings last quarter?
Edesa Biotech Inc released its earnings results on Aug 08, 2025. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.263 by $0.013.
Is Edesa Biotech Inc overvalued?
According to Wall Street analysts Edesa Biotech Inc’s price is currently Undervalued.
Does Edesa Biotech Inc pay dividends?
Edesa Biotech Inc does not currently pay dividends.
What is Edesa Biotech Inc’s EPS estimate?
Edesa Biotech Inc’s EPS estimate is -0.28.
How many shares outstanding does Edesa Biotech Inc have?
Edesa Biotech Inc has 7,037,648 shares outstanding.
What happened to Edesa Biotech Inc’s price movement after its last earnings report?
Edesa Biotech Inc reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.263. Following the earnings report the stock price went down -0.472%.
Which hedge fund is a major shareholder of Edesa Biotech Inc?
Currently, no hedge funds are holding shares in EDSA
Company Description
Edesa Biotech Inc
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Technical Analysis
Eterna Therapeutics
―
Lipocine
―
XTL Biopharmaceuticals Sponsored ADR
―
Cocrystal Pharma
―
BioVie
―
Ownership Overview
19.22% Insiders
0.55% Mutual Funds
28.42% Other Institutional Investors
51.35% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---